Stem Cells for Crohn's Fistulas: A Rare Approved MSC Therapy, Examined

Most of the time, when we write about stem cells, the honest verdict is "promising, but unproven" — exciting biology running ahead of the evidence. So it's worth highlighting a genuine exception: a stem-cell therapy that actually cleared the regulatory bar, backed by a proper phase 3 trial. It's called darvadstrocel, and it treats a specific, miserable complication of Crohn's disease. It's not flashy, and that's precisely the point — it's a model of what legitimate stem-cell medicine looks like ¹.

Reading it well is useful in two ways: it shows what works, and it sharpens your eye for the much larger world of stem-cell claims that don't.

What question did the researchers ask?

The researchers asked whether injecting mesenchymal stem cells (MSCs) directly into complex perianal fistulas — abnormal, painful tunnels that form near the anus in some people with Crohn's disease — could help them heal when standard treatments had failed ¹.

A few details matter. The cells are allogeneic (from a healthy donor, not the patient) and adipose-derived (grown from fat tissue). Crucially, they're delivered locally — injected into and around the fistula tract during a procedure — not infused into the bloodstream. This is a targeted repair of a specific problem, which is part of why it could be tested and approved where vaguer "stem cell" approaches can't. If MSCs are new to you, our stem-cell overview gives the background.

What did the trial find?

The pivotal ADMIRE-CD phase 3 trial compared the stem-cell injection with a control. More patients treated with the stem cells reached combined remission — meaning the fistula openings had closed on clinical examination and there was no significant fluid collection on MRI — than in the control group, and the benefit was maintained at 52 weeks (one year) ¹. Later analyses and a 2025 review of MSC therapies for this condition support the same overall picture: a real, if modest, benefit with a reassuring safety profile ².

On that evidence, darvadstrocel was approved by regulators in the European Union, the UK, Japan and other countries for complex perianal fistulas in Crohn's that haven't responded to conventional or biologic therapy. That regulatory approval is the headline: this is a stem-cell therapy that genuinely earned its place in medicine.

How strong is this evidence — and what are the limits?

It's strong by stem-cell standards: a randomised phase 3 trial with a meaningful, durable benefit and regulatory approval behind it. But it's worth being clear about the limits, too. The effect is real but modest — it improves the odds of healing, it doesn't guarantee it — and some patients still won't reach remission. It also treats only the fistula, not Crohn's disease itself, which still needs its usual management. And it's not approved everywhere (notably not in the US), so availability varies.

The deeper value of this example is what it teaches about evidence. Darvadstrocel works because it was developed properly: a defined cell product, a specific condition, local delivery, and a real trial. That's the opposite of the "stem cells for everything, infused into a vein" marketing that dominates the wider field — and a useful yardstick to judge any stem-cell offer against.

What could this mean if you are considering treatment?

If you have Crohn's disease with complex perianal fistulas that haven't responded to standard or biologic treatment, this is a legitimate, approved option worth discussing with a gastroenterologist or colorectal specialist — in the countries where it's available. The questions to ask are practical: Am I a candidate? Is it available here? What does the procedure and follow-up involve, and what are realistic expectations?

Just as important is what this isn't: it isn't an intravenous "stem cell infusion", it isn't a treatment for Crohn's in general, and it has nothing to do with anti-ageing or wellness uses of stem cells. Keeping those distinctions clear protects you from less reputable offers.

What we see at the clinic

As a regenerative-medicine clinic, we think darvadstrocel is genuinely worth pointing to — because it's proof that stem-cell therapy can be done right: narrowly, locally, and with real trial evidence. We use it as a benchmark when people ask us about stem-cell treatments, because it highlights the gap between a properly developed, approved therapy and the broad, unproven "stem cell" infusions marketed for almost everything. Honest regenerative medicine looks more like this than like the hype.

Common questions

Is this the same as a stem-cell infusion? No. Darvadstrocel is injected locally into the fistula, not infused into a vein, and it treats one specific problem ¹.

Does it cure Crohn's disease? No. It treats complex perianal fistulas; Crohn's itself still needs its usual medical management.

Is it available everywhere? No. It's approved in the EU, UK, Japan and some other countries, but not universally (not in the US), so access depends on where you are.

[1] ADMIRE-CD: long-term efficacy and safety of darvadstrocel for complex perianal fistulas in Crohn's disease (phase 3 randomized controlled trial). https://pmc.ncbi.nlm.nih.gov/articles/PMC8985696/

Key takeaway

Darvadstrocel is a rare thing: a stem-cell therapy that genuinely earned regulatory approval, by treating one specific, hard problem — complex perianal fistulas in Crohn's disease — with locally injected donor MSCs, tested in a real phase 3 trial. The benefit is real if modest, it treats only the fistula, and it isn't available everywhere. Most of all, it's a model of what legitimate stem-cell medicine looks like: narrow, proven and approved — a world apart from "stem cells for everything" marketing.